Search Tag: bevacizumab

Cardiology Management

Study-bevacizumab-increases-risk-of-arterial-adverse-events

2017 12 Sep

The monoclonal antibody bevacizumab effectively inhibits angiogenesis in several types of cancers by blocking vascular endothelial growth factor. However, a new analysis reveals that treatment with bevacizumab increases the risk of arterial adverse events, particularly cardiac and cerebral ischaemia, venous adverse events, bleeding, and arterial hypertension....Read more